Treating adult patients of severe psoriasis with methotrexate leads to reduction in biomarkers of atherosclerosis: A prospective study

Q2 Medicine

Medical Journal Armed Forces India Pub Date : 2024-12-01 DOI:10.1016/j.mjafi.2023.03.004

Shekhar Neema , Biju Vasudevan , Pratibha Misra , Roma Rai , M.K. Sibin , Senkadhir Vendhan , Shantanu Banerjee , Vinay Gera , A.K. Yadav

{"title":"Treating adult patients of severe psoriasis with methotrexate leads to reduction in biomarkers of atherosclerosis: A prospective study","authors":"Shekhar Neema , Biju Vasudevan , Pratibha Misra , Roma Rai , M.K. Sibin , Senkadhir Vendhan , Shantanu Banerjee , Vinay Gera , A.K. Yadav","doi":"10.1016/j.mjafi.2023.03.004","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Psoriasis<span><span> is a common skin disorder; affecting 0.4–2% of general population and is associated with increased risk of cardiovascular diseases. We conducted this prospective study to determine change in biomarkers of </span>atherosclerosis<span><span> in plaque psoriasis in patients treated with </span>methotrexate.</span></span></div></div><div><h3>Methods</h3><div>The study was carried out at a tertiary care centre over a period of 1 year after institutional ethical clearance. The study included 50 patients. Adults with severe psoriasis not receiving any systemic treatment<span><span><span> for last 3 months were included in the study. Clinical parameters including psoriasis area and severity index (PASI), </span>dermatology </span>quality of life index (DLQI) and estimation of IL-6, hsCRP, and HDL levels and LDL: HDL ratio were done at baseline and at 12 weeks.</span></div></div><div><h3>Results</h3><div>A total of 50 patients were included and 42 completed the study. The mean age and mean duration of disease was 44.4 (±13.2) years and 10.8 (±9.9) years, respectively. Pre- and post-treatment mean PASI was 16.3 (±8.3) and 7.43 (±4.9), respectively (<em>p</em> = 0.001). The level of VEGF, IL-6, and hsCRP was 127 (±158) pg/ml, 5.3 (±2.5) pg/ml, and 4.2 (±4.1) mg/L, respectively. The levels of VEGF, IL-6, and hsCRP after 12 weeks of treatment were found to be 59.3 (±61) pg/ml (<em>p</em>=0.006), 3.6 (±2.1) pg/ml (<em>p</em> < 0.001), and 2.6 (±3.1) mg/L (<em>p</em> = 0.012), respectively.</div></div><div><h3>Conclusion</h3><div><span>Methotrexate use in patients with chronic plaque psoriasis reduces the level of biomarkers of </span>atherosclerosis<span> at 12 weeks. Early treatment with methotrexate may help in reduction of cardiovascular risk in psoriasis patients.</span></div></div>","PeriodicalId":39387,"journal":{"name":"Medical Journal Armed Forces India","volume":"80 ","pages":"Pages S174-S179"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Journal Armed Forces India","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0377123723000370","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Psoriasis is a common skin disorder; affecting 0.4–2% of general population and is associated with increased risk of cardiovascular diseases. We conducted this prospective study to determine change in biomarkers of atherosclerosis in plaque psoriasis in patients treated with methotrexate.

Methods

The study was carried out at a tertiary care centre over a period of 1 year after institutional ethical clearance. The study included 50 patients. Adults with severe psoriasis not receiving any systemic treatment for last 3 months were included in the study. Clinical parameters including psoriasis area and severity index (PASI), dermatology quality of life index (DLQI) and estimation of IL-6, hsCRP, and HDL levels and LDL: HDL ratio were done at baseline and at 12 weeks.

Results

A total of 50 patients were included and 42 completed the study. The mean age and mean duration of disease was 44.4 (±13.2) years and 10.8 (±9.9) years, respectively. Pre- and post-treatment mean PASI was 16.3 (±8.3) and 7.43 (±4.9), respectively (p = 0.001). The level of VEGF, IL-6, and hsCRP was 127 (±158) pg/ml, 5.3 (±2.5) pg/ml, and 4.2 (±4.1) mg/L, respectively. The levels of VEGF, IL-6, and hsCRP after 12 weeks of treatment were found to be 59.3 (±61) pg/ml (p=0.006), 3.6 (±2.1) pg/ml (p < 0.001), and 2.6 (±3.1) mg/L (p = 0.012), respectively.

Conclusion

Methotrexate use in patients with chronic plaque psoriasis reduces the level of biomarkers of atherosclerosis at 12 weeks. Early treatment with methotrexate may help in reduction of cardiovascular risk in psoriasis patients.

查看原文本刊更多论文

甲氨蝶呤治疗严重银屑病的成年患者可降低动脉粥样硬化的生物标志物:一项前瞻性研究

背景：牛皮癣是一种常见的皮肤病；影响总人口的0.4% - 2%，并与心血管疾病的风险增加有关。我们进行了这项前瞻性研究，以确定接受甲氨蝶呤治疗的斑块型银屑病患者动脉粥样硬化生物标志物的变化。方法：该研究在经过机构伦理审查后，在一家三级保健中心进行了为期1年的研究。该研究包括50名患者。过去3个月未接受任何系统治疗的严重牛皮癣成人纳入研究。临床参数包括牛皮癣面积和严重程度指数（PASI）、皮肤病生活质量指数（DLQI）以及IL-6、hsCRP、HDL水平和LDL: HDL比值的估计在基线和12周时完成。结果共纳入50例患者，42例完成研究。平均年龄为44.4（±13.2）岁，平均病程为10.8（±9.9）岁。治疗前和治疗后的平均PASI分别为16.3（±8.3）和7.43（±4.9）（p = 0.001）。VEGF、IL-6、hsCRP水平分别为127（±158）pg/ml、5.3（±2.5）pg/ml、4.2（±4.1）mg/L。治疗12周后VEGF、IL-6、hsCRP水平分别为59.3（±61）pg/ml （p=0.006）、3.6（±2.1）pg/ml (p <；0.001),和2.6(±3.1)mg / L (p = 0.012),分别。结论甲氨蝶呤可降低慢性斑块型银屑病患者12周动脉粥样硬化生物标志物水平。早期用甲氨蝶呤治疗可能有助于降低银屑病患者的心血管风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Medical Journal Armed Forces India Medicine-Medicine (all)

CiteScore

3.40

自引率

0.00%

发文量

206

期刊介绍： This journal was conceived in 1945 as the Journal of Indian Army Medical Corps. Col DR Thapar was the first Editor who published it on behalf of Lt. Gen Gordon Wilson, the then Director of Medical Services in India. Over the years the journal has achieved various milestones. Presently it is published in Vancouver style, printed on offset, and has a distribution exceeding 5000 per issue. It is published in January, April, July and October each year.